ACTU
ACTUATE THERAPEUTICS, INC.
Next earnings Aug 14, 2026 · consensus $-0.19 EPS
$1.68
▼ -14.29%$1.68▼ -77.51%
over 1Y
L $1.68EODHDH $8.72
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-14.3%
1W-14.3%
1M-20.4%
3M-21.9%
YTD-72.1%
1Y-77.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy
Conservative balance sheet (liabilities/equity 0.77x).
ACTUATE THERAPEUTICS, INC. shows limited reported revenue, and -280.5% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$25.0M | -$25.2M | -$22.5M |
| Net income | -$24.7M | -$27.3M | -$22.2M |
| Diluted EPS | -$17.24 | -$3.26 | -$1.06 |
| Net margin | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$26.7M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-55.8%
FCF yield—
Quality & risk
ROIC (est.)-224.3%
Free cash flow—
Total debt—
Net cash$13.2M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+21.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗S-8Filing2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-112026-05-11open ↗3Period ending 2026-05-012026-05-06open ↗
Frequently asked
- Is ACTUATE THERAPEUTICS, INC. (ACTU) a buy?
- ACTU currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.77x).
- What is ACTUATE THERAPEUTICS, INC.'s quality score?
- ACTU scores 53.71794871794872/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001652935, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 8:03:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.